LONDON (Alliance News) - Specialty pharmaceuticals company BTG PLC maintained its revenue guidance for its current financial year on Wednesday, saying it has made a good start to the year.
BTG said it is trading in line with its expectations in its financial first quarter that ended June 30 and said its full-year revenue guidance remains at GBP410 million to GBP440 million. The company posted revenue of GBP367.8 million for its 2015 financial year to the end of March.
The company said the controlled launch of its Varithena injectable foam product in the US reimbursed sector has continued, with the number of physicians having enrolled for training increased to 468 in the quarter. The group is increasing is Varithena sales team in order to further expand its presence in the physician sector.
Sales of its EkoSonic blood clot treatment has continued to increase, with more hospitals in the US adopting the product.
BTG added that within its specialty pharmaceuticals franchise, sales of its CroFab, DigiFab and Voraxaze antidote products have been in line with expectations, as has royalty revenue from is licenced products.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
